8月25日,，英國(guó)劍橋大學(xué)發(fā)布公報(bào)說(shuō)，該校研究人員成功利用肝病患者的皮膚細(xì)胞培育出肝臟細(xì)胞,，這樣得到的肝臟細(xì)胞與病人肝臟中的細(xì)胞高度相似,，將有助于對(duì)特定肝病患者進(jìn)行研究并開展治療。
公報(bào)說(shuō),，研究人員從7名有遺傳性肝臟疾病的患者身上提取了皮膚細(xì)胞,，先將其改變?yōu)檎T導(dǎo)多能干細(xì)胞，然后培育成肝臟細(xì)胞,。誘導(dǎo)多能干細(xì)胞技術(shù)是2007年日美科學(xué)家的一項(xiàng)重大研究成果,，它可以對(duì)皮膚細(xì)胞進(jìn)行改造，使其具有與干細(xì)胞相似的功能,。
本次研究顯示,，利用這種方法得到的肝臟細(xì)胞在生理特征上與病人肝臟中的細(xì)胞高度相似,，因此可用于試驗(yàn)各種藥物,，驗(yàn)之有效后再對(duì)病人進(jìn)行治療,。
研究報(bào)告發(fā)表在新一期《臨床研究雜志》上,。（生物谷Bioon.com）
生物谷推薦原文出處：
J Clin Invest. doi:10.1172/JCI43122.
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells
S. Tamir Rashid1,2, Sebastien Corbineau1,3, Nick Hannan1, Stefan J. Marciniak2, Elena Miranda2,4, Graeme Alexander5, Isabel Huang-Doran6, Julian Griffin6, Lars Ahrlund-Richter7, Jeremy Skepper8, Robert Semple6, Anne Weber3, David A. Lomas2 and Ludovic Vallier1
1Laboratory for Regenerative Medicine and
2Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
3INSERM U972, University Paris-Sud, IFR 69, H?pital du Kremlin-Bicêtre, Le Kremlin-Bicêtre, France.
4Department of Cell Biology and Development, Universita’ “La Sapienza,” Rome, Italy.
5Department of Medicine, School of Clinical Medicine, and
6University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.
7Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
8Department of Physiology, Development and Neuroscience, Multi-Imaging Centre School of Biological Sciences, University of Cambridge, Cambridge, United Kingdom.
Human induced pluripotent stem (iPS) cells hold great promise for advancements in developmental biology, cell-based therapy, and modeling of human disease. Here, we examined the use of human iPS cells for modeling inherited metabolic disorders of the liver. Dermal fibroblasts from patients with various inherited metabolic diseases of the liver were used to generate a library of patient-specific human iPS cell lines. Each line was differentiated into hepatocytes using what we believe to be a novel 3-step differentiation protocol in chemically defined conditions. The resulting cells exhibited properties of mature hepatocytes, such as albumin secretion and cytochrome P450 metabolism. Moreover, cells generated from patients with 3 of the inherited metabolic conditions studied in further detail (α1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease type 1a) were found to recapitulate key pathological features of the diseases affecting the patients from which they were derived, such as aggregation of misfolded α1-antitrypsin in the endoplasmic reticulum, deficient LDL receptor–mediated cholesterol uptake, and elevated lipid and glycogen accumulation. Therefore, we report a simple and effective platform for hepatocyte generation from patient-specific human iPS cells. These patient-derived hepatocytes demonstrate that it is possible to model diseases whose phenotypes are caused by pathological dysregulation of key processes within adult cells.
